Dr. Reddy’s Reports Q2 FY27 Financial Results
Dr Reddys Laboratories Ltd · Investor Presentation · 23 Oct 2026, 11:07 pm
Dr. Reddy’s Reports Q2 FY27 Financial Results Dr. Reddy’s posted Q2 FY27 revenue of ₹8,671 Cr, down 1.5% YoY but up 7% QoQ, impacted by lower lenalidomide sales despite double-digit base business growth. EBITDA fell 24% YoY to ₹1,783 Cr (20.6% margin), while PAT declined 36% YoY to ₹925 Cr. Segmentally, Global Generics stood at ₹7,793 Cr, driven by Emerging Markets (+24% YoY) and India (+17% YoY), offsetting North America (-23% YoY). Aurigene CDMO crossed $100+ million annual revenue. Net cash surplus closed at ₹2,502 Cr as of 30th Sep'26.
Original exchange filing (PDF)
More announcements from Dr Reddys Laboratories Ltd
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 14 Nov 2026
- Intimation of Analyst meet · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 05 Nov 2026
- Allotment of Employee Stock options · 04 Nov 2026
- Clarification - Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 04 Nov 2026
- The Exchange has sought Clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.firstpost.com dated November 03, 2026 (Link : https://www.firstpost.com/business/indias-dr-reddys-gets-us-nod-for-40-generic-hiv-prevention-shot-for-120-poorer-countries-14057224.html) .... · 03 Nov 2026
- Transcript of Earnings call · 30 Oct 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 · 28 Oct 2026
